Evidence map›Paper›PMID 39630300›Full record

ArticleDiscover oncology2024

CMTM6 status predicts survival in head and neck squamous cell carcinoma and correlates with PD-L1 expression.

Anne-Sophie Becker, Nicolas Wieder, Sarah Zonnur, Annette Zimpfer, Mareike Krause, Björn Schneider, Daniel Fabian Strüder, Ann-Sophie Burmeister, Andreas Erbersdobler, Christian Junghanss and 1 more

Abstract read
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anne-Sophie BeckerInstitute of Pathology, Rostock University Medical Center, Strempelstr. 14, 18057, Rostock, Germany. anne-sophie.becker@med.uni-rostock.de.
Nicolas WiederDepartment of Neurology With Experimental Neurology, Berlin Institute of Health, Charite´, 10117, Berlin, Germany.
Sarah ZonnurInstitute of Pathology, Rostock University Medical Center, Strempelstr. 14, 18057, Rostock, Germany.
Annette ZimpferInstitute of Pathology, Rostock University Medical Center, Strempelstr. 14, 18057, Rostock, Germany.
Mareike KrauseDepartment of Internal Medicine, Medical Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Björn SchneiderInstitute of Pathology, Rostock University Medical Center, Strempelstr. 14, 18057, Rostock, Germany.
Daniel Fabian StrüderDepartment of Otorhinolaryngology, Head and Neck Surgery "Otto Koerner", Rostock University Medical Center, Rostock, Germany.
Ann-Sophie BurmeisterDepartment of Internal Medicine, Medical Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Andreas ErbersdoblerInstitute of Pathology, Rostock University Medical Center, Strempelstr. 14, 18057, Rostock, Germany.
Christian JunghanssDepartment of Internal Medicine, Medical Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Claudia MaletzkiDepartment of Internal Medicine, Medical Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.

Funding

Rostock University Medical center 889038
6 · The paper itself

Abstract

We retrospectively analyzed 129 treatment-naïve head and neck squamous cell carcinomas (HNSCCs) for the expression of programmed death ligand 1 (PD-L1), CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6), tumor-infiltrating leukocytes (TILs), and tumor-associated macrophages (TAMs). We evaluated the relationships among these markers, human papilloma virus (HPV) status, and overall survival (OS). PD-L1 and CMTM6 (combined positive score (CPS) ≥ 1 and ≥ 5) were detected in ~ 70% of HNSCCs. HPV status had insignificant effects on marker expression. Most PD-L1-positive cases showed concomitant CMTM6 expression with comparable staining patterns. While PD-L1 and CMTM6 mRNA expression levels correlated with PD-L1 and CMTM6 protein status, no significant correlation was observed for PD-L1 and CMTM6 mRNA expression. Tumors expressing PD-L1 (p < 0.0001) and/or CMTM6 (p < 0.05) were associated with the best OS. A high density of TILs (p < 0.01), CD8

Indexed as

CMTM6HNSCCOverall survivalProgrammed death ligand 1TIL

Identifiers

PMID39630300
PMCPMC11618569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.